Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Q4 2023 Pharmacy & Infusion Services Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Q4 2023 Pharmacy & Infusion Services Update

In Q4-23, healthcare providers continued expanding upon their home infusion service lines as site-of-care strategies grow in importance. The COVID-19 pandemic increased demand for home-based care, boosting growth in the home infusion therapy sector. Home infusion therapy offers various benefits including convenience, cost-effectiveness, better outcomes, and higher safety standards.

Pharmacy services are also shifting towards more home and community-based settings as highlighted by the Nightingale HomeCare/Infusion/Pharmacy transaction, which Provident was the exclusive financial advisor on.

Although infusion and pharmacy deals saw a slight dip in Q4-23, according to investors, it will be a main area of focus in 2024.

To print and download the full Pharmacy & Infusion Services Update report, please click below…

[holo_button icon=”/wp-content/uploads/2024/01/Q4-2023-Pharmacy-Infusion-Newsletter.pdf” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]